Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance
Conclusions: We conclude that TDM is an effective method of achieving targeted Bu levels in children. QC programs are crucial to monitoring and maintaining the quality of an analytical method.
We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
The PD-1/PD-L1 (programmed cell death) pathway is an immune checkpoint, which protects normal tissues but can also prevent anti-tumor immune response. The FDA approvals of checkpoint inhibitors constitutes a major advance in the immunotherapy of cancer . Chronic myeloid leukemia (CML) is an example of successful use of tyrosine kinase inhibitors (TKIs). Blockade of oncogenic BCR-ABL1 kinase activity translated into an impressive control of the disease. CML is also known to be responsive to immunotherapy and long-term eradication of CML has been achieved by allogeneic hematopoietic stem cell transplantation .
Immunoglobulin light chain amyloidosis (AL) is the most common form of systemic amyloidosis . It is a monoclonal plasma cell disorder characterized by misfolded immunoglobulin free light chain accumulation as amyloid fibrils in multiple organs causing organ dysfunction . The aim of therapy in AL is to eliminate the plasma cell clone to reduce the production of misfolded light chains and to preserve organ function. The treatment of AL is patterned after multiple myeloma, another clonal plasma cell disorder.
Unmanipulated haploidentical PBSC transplantation following RIC with ATG, PT-CY and cyclosporine as a GVHD prevention strategy results in low rates of acute and chronic GVHD.
Relapse is the most important cause of failure in the treatment of acute myeloid leukemia (AML). The European Leukemia Net (ELN) recommends allogeneic stem cell transplantation (alloSCT) in AML patients in first complete remission after a careful risk-benefit assessment1. Here, disease specific and transplantation specific risk factors have to be evaluated before a recommendation for an alloSCT can be given. Generally, alloSCT is recommended if disease relapse risk exceeds 35 to 40% without the procedure.
CONCLUSIONS: The results of this series are comparable to the results of other international series and offer a platform from which to continue trying to improve the evolution of these patients. PMID: 30001893 [PubMed - as supplied by publisher]
AbstractPurpose of ReviewOutcomes for older adults with acute lymphoblastic leukemia (ALL) remain poor, and allogeneic hematopoietic stem cell transplant (HSCT) remains a potentially curative modality. However, benefits are offset by high rates of non-relapse mortality (NRM) in patients undergoing myeloablative conditioning (MAC) regimens. Reduced intensity conditioning (RIC) regimens can extend this therapy to adults who are unfit for MAC, although at the cost of higher relapse rates. In this review, we discuss evidence to support the usage of RIC regimens, controversies, and potential strategies to improve transplant out...
CONCLUSION: Current recommendations for the treatment of primary CNS lymphomaare based on only a small number of prospective clinical trials. Patients with this disease should be treated by interdisciplinary teams in experienced centers, andpreferably as part of a controlled trial. PMID: 29999484 [PubMed - in process]
ConclusionsWe constructed a model to better predict PTLD compared to EBV DNA screening alone which could have clinical implications.
Condition: Interventional Intervention: Other: MSC transplantation Sponsors: University Medical Centre Ljubljana; Slovenian Research Agency Not yet recruiting